Drug Trial Radar · NCT04053764
Study Exploring the Effect of Crizanlizumab on Kidney Function in Patients With Chronic Kidney Disease Caused by Sickle Cell Disease
Last checked: Nov 20, 2026Latest source record: Oct 9, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
58
Actual
Start
Dec 10, 2019
Primary completion
Mar 20, 2023
Study completion Mar 20, 2023
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Aug 12, 2019
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of the study was to evaluate descriptively the effect of crizanlizumab + standard of care and standard of care alone on renal function in sickle cell disease patients ≥ 16 years with chronic kidney disease due to sickle cell nephropathy.
Conditions
- Sickle Cell Disease (SCD)
Interventions
CrizanlizuambDrug
Crizanlizumab is a concentrate for solution for infusion, i.v. use. Supplied in single use 10 mL vials at a concentration of 10 mg/mL. One vial contains 100 mg of crizanlizumab
Standard of CareDrug
HU/HC (hydroxyurea/hydroxycarbamide) and/or ACE (angiotensin-converting enzyme) inhibitors and/or ARBs (angiotensin-receptor blocker)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants With ≥ 30% Decrease in Albuminuria (ACR) at 12 MonthsTime frame: Baseline to 12 months
Locations
24 sites in 11 countries. Site status is shown where the registry gives one.
University of Alabama Birmingham
Birmingham, Alabama
University of Illinois Hospital and Health Sciences System .
Chicago, Illinois
Our Lady of the Lake Regional Medic .
Baton Rouge, Louisiana
East Carolina University BrodySchool of Med 3
Greenville, North Carolina
Univ of Tenn Health Sciences Ctr
Memphis, Tennessee
University of Texas Health Science Center at Houston
Houston, Texas
Novartis Investigative Site
Porto Alegre, Brazil
Novartis Investigative Site
Rio de Janeiro, Rio de Janeiro, Brazil
Novartis Investigative Site
São Paulo, São Paulo, Brazil
Novartis Investigative Site
Créteil, France
Novartis Investigative Site
Paris, France
Novartis Investigative Site
Athens, Greece
Novartis Investigative Site
Larissa, Greece
Novartis Investigative Site
Dublin, Ireland
Novartis Investigative Site
Tripoli, Lebanon
Novartis Investigative Site
Amsterdam, Netherlands
Novartis Investigative Site
Panama City, Panama
Novartis Investigative Site
Barcelona, Catalonia, Spain
Novartis Investigative Site
Adana, Turkey (Türkiye)
Novartis Investigative Site
Adana, Turkey (Türkiye)
Novartis Investigative Site
Antakya / Hatay, Turkey (Türkiye)
Novartis Investigative Site
London, United Kingdom
Novartis Investigative Site
London, United Kingdom
Novartis Investigative Site
London, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.